Return to List

Study Summary
No. ID02-115:.............Judith Wolf......Gynecologic Oncology
.
Study Summary Title
Study Summary
Number:		ID02-115
Study Title:A Phase I/II Study to Evaluate the Optimum Dose of Pegylated-Interferon (PEG INTRON) in Patients with Platinum Resistant Ovarian, Peritoneal or Fallopian Tube Cancer
.
Physician New Patient Referral
Name:Judith WolfPatients Call:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Dept:Gynecologic OncologyReferring MD
Call:		800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Phone:713-792-7310
Contact us about clinical trials
.
General Information
Disease Group:Supported By:N/A
Phase of Study:Phase I/Phase IIReturn
Visit:		Q28 days
Treatment
Agents:		Home Care:N/A
Treatment Loc:Only at MDACC
Estimated
Length of Stay
in Houston:		N/A
Description/
Intervention:		The goal of this clinical research study is to find the optimum biologic dose
(OBD) of PEG Intron that can be given as a treatment for patients with ovarian,
peritoneal, or fallopian tube cancer. Researchers hope to find out if PEG
Intron will help shrink or slow the growth of tumors in patients who are
considered resistant to platinum drugs. The safety of this drug will also be
studied
.
Study Objectives / Outcomes
1. To identify the optimum biologic dose of PEG Intron in patients with platinum-resistant ovarian, fallopian tube or peritoneal cancer whose tumors test positive for IL-8, BFGF, or VEGF.
2. To assess the safety and tolerability of this agent in this patient population.
3. Evaluate the modulation of a panel of biomarkers drawn pretreatment, at specified timepoints during therapy and at the end of treatment.
.
Study Status Information
Study Activation / Registration Date:07/10/2002
IRB Review and Approval Date:05/15/2002
Study Type:Therapeutic
Recruitment Status:Terminated
Projected Accrual:100
.
Enrollment Eligibility
If you do not meet the enrollment eligibility, there may be other treatment options for you. Please Contact the Referral Office for more information.
Inclusion Criteria:Unavailable
Exclusion Criteria:Unavailable
.
Links
Registration Number: NCT00085384
Study Information on Clinical Trials Registry (clinicaltrials.gov)
Other Links:
.
Results

Return to Clinical Trials at M.D. Anderson Cancer Center